Skip to main content
Addgene

-161+80pCalb2/mutE2F(-69)-like
(Plasmid #66743)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 66743 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pGL3 basic
  • Backbone manufacturer
    Promega
  • Backbone size w/o insert (bp) 4818
  • Vector type
    Mammalian Expression, Luciferase

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    Calb2 promoter (-161bp+80)
  • Alt name
    calbindin 2
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    241
  • Mutation
    GCG (-69,-68,-67) to ATT
  • GenBank ID
    794
  • Entrez Gene
    CALB2 (a.k.a. CAB29, CAL2, CR)
  • Promoter Calb2
  • Tag / Fusion Protein
    • luciferase (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site HindIII (not destroyed)
  • 3′ cloning site NcoI (not destroyed)
  • 5′ sequencing primer REVprimer3
  • 3′ sequencing primer GLprimer2
    • (Common Sequencing Primers)

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    -161+80pCalb2/mutE2F(-69)-like was a gift from Emanuela Felley-Bosco & Rolf Stahel (Addgene plasmid # 66743 ; http://n2t.net/addgene:66743 ; RRID:Addgene_66743)

  • For your References section:

    Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells. Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, Johnson KC, Schwaller B, Weder W, Stahel RA, Felley-Bosco E. Oncotarget. 2016 Feb 1. doi: 10.18632/oncotarget.7114. 10.18632/oncotarget.7114 PubMed 26848772
Related items: